Primary signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report

Abstract

IntroductionPrimary signet-ring cell carcinoma of the urinary bladder is a rare variant of mucus-producing adenocarcinoma constituting approximately 0.5% to 2.0% of all primary carcinomas of the bladder. This tumor initially presents as a high-grade, high-stage lesion and diffusely invades the bladder wall without forming intraluminal growth. The patients have no specific symptoms, which leads to delayed diagnosis and poor prognosis.Case presentationWe report the case of a 51-year-old Moroccan Berber man consulting for gross hematuria. Ultrasonography and a computed tomography scan found a bladder tumor diffusely invading the bladder wall. A histopathological examination of the tumor chips from a transurethral resection of the bladder revealed signet-ring cell adenocarcinoma. The gastrointestinal tract exploration did not reveal any other tumor localization. A radical cystectomy and adjuvant cisplatin and gemcitabine chemotherapy were therefore performed resulting in 18 months of survival without metastasis and a good quality of life within that time.ConclusionThe rarity and the successful management with carboplatin and gemcitabine as adjuvant chemotherapy of this entity, which is rarely reported in the literature, are two remarkable characteristics described in this case report.

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data

“…In CRC, these markers are elevated in approximately one third (CA125), half (CA19-9), and two-thirds (CEA) of patients with a considerable variance depending on tumor size and other variables [ 358 ]. In primary bladder adenocarcinomas, however, only sporadic data is available with reports of elevated serum levels of these markers [ 359 , 360 ].…”

Primary signet-ring cell carcinoma of the urinary bladder

“…2,20 When a cisplatinbased combined chemotherapy regimen follows surgical therapy, it improves the progression-free and overall survival. 21 The index case underwent partial cystectomy with standard pelvic lymph node dissection. In follow up, the patient received 3 cycles of adjuvant chemotherapy and is currently disease-free on follow up.…”

Microangiopathic hemolytic anemia caused by a signet-ring cell carcinoma of the intrahepatic bile duct

“…It is a dedifferentiated adenocarcinoma, histologically characterized by round-shaped cells, with peripherally placed nuclei and cytoplasmic vacuoles filled with mucin [7,8]. SRCC is usually located in the stomach but can also be found in other tissues like prostate [9], breast [10], testis [11] and ovary [12], bladder [13], lung [14], colon [15], gallbladder [16] and Vater ampulla [17]. To the best of our knowledge only 5 cases of SRCC of the bile ducts are described in literature, all of them referring to extrahepatic bile ducts SRCC [18,19,20,21,22].…”